TEM vs. EXAS: Which Genomics Player Offers Greater Upside?

Key Takeaways Tempus AI's Genomics revenues jumped 115% year over year, driven by testing growth and acquisitions. Exact Sciences' genomics advances include Oncotype DX and Oncodetect validation in colorectal cancer. EXAS offers a stronger earnings outlook and valuation appeal, while TEM leads in share performance. Per multiple sources, the integration of genomics into cancer care has transformed treatment approaches, moving away from uniform therapies to precision medicine, where clinical decisions are tai ...